<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3001233195
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pifeltro
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DORAVIRINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1361.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD INTERNATIONAL GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD INTERNATIONAL GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Sharp & Dohme B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Pifeltro is</strong></p><p>Pifeltro is used to treat HIV (&lsquo;human immunodeficiency virus&rsquo;) infection. It belongs to a group of medicines called &lsquo;antiretroviral medicines&rsquo;.</p><p>&nbsp;</p><p>Pifeltro contains the active substance doravirine - a non‑nucleoside reverse transcriptase inhibitor (NNRTI).</p><p>&nbsp;</p><p><strong>What Pifeltro is used for</strong></p><p>Pifeltro is used to treat HIV infection in adults, and adolescents aged 12&nbsp;years and older weighing at least 35&nbsp;kg. HIV is the virus that causes AIDS (&lsquo;acquired immune deficiency syndrome&rsquo;). You should not take Pifeltro if your doctor has told you that the virus causing your infection is resistant to doravirine.</p><p>&nbsp;</p><p>Pifeltro must be used in combination with other medicines for HIV.</p><p>&nbsp;</p><p><strong>How Pifeltro works</strong></p><p>When used with other medicines, Pifeltro works by preventing HIV from making more viruses in your body. This will help by:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reducing the amount of HIV in your blood (this is called your &lsquo;viral load&rsquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increasing the number of white blood cells called &lsquo;CD4<sup>+</sup> T&rsquo;. This can make your immune system stronger. This may reduce your risk of early death or catching infections because your immune system is weak.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Pifeltro</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to doravirine or any of the other ingredients of this medicine listed in section&nbsp;6.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking the following medicines:</p><p>- carbamazepine, oxcarbazepine, phenobarbital, phenytoin (medicines for seizures)</p><p>- rifampicin, rifapentine (medicines for tuberculosis)</p><p>- St. John&rsquo;s wort (<em>Hypericum perforatum</em>, a herbal remedy used for depression and anxiety) or products that contain it</p><p>- mitotane (a medicine to treat cancer)</p><p>- enzalutamide (a medicine to treat prostate cancer)</p><p>- lumacaftor (a medicine to treat cystic fibrosis)</p><p>&nbsp;</p><p>Do not take Pifeltro if the above applies to you. If you are not sure, talk to your doctor, pharmacist, or nurse before taking Pifeltro. See also &ldquo;Other Medicines and Pifeltro&rdquo; section.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist, or nurse before taking Pifeltro.</p><p><strong>&nbsp;</strong></p><p><strong>Immune reactivation syndrome</strong></p><p>This can happen when you start taking any HIV medicine, including this medicine. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your doctor right away if you start having any new symptoms after starting your HIV medicine.</p><p>&nbsp;</p><p>Autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>Do not give this medicine to children aged less than 12&nbsp;years </strong><strong>or weighing less than 35&nbsp;kg</strong><strong>.</strong> The use of Pifeltro in children aged less than 12&nbsp;years or weighing less than 35&nbsp;kg has not yet been studied.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Pifeltro</strong></p><p>Tell your doctor, pharmacist, or nurse if you are taking, have recently taken or might take any other medicines. This is because other medicines may affect how Pifeltro works, and Pifeltro might affect the way some other medicines work.</p><p>&nbsp;</p><p>There are some medicines you must not take with Pifeltro. See list under &ldquo;Do not take Pifeltro&rdquo; section.</p><p>&nbsp;</p><p>Talk to your doctor before taking the following medicines with Pifeltro, as your doctor may need to change the dose of your medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bosentan (a medicine to treat lung disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dabrafenib (a medicine to treat skin cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lesinurad (a medicine to treat gout)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; modafinil (a medicine to treat excessive sleepiness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nafcillin (a medicine to treat some bacterial infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin (a medicine to treat some bacterial infections such as tuberculosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; telotristat ethyl (a medicine to treat diarrhoea in people with carcinoid syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thioridazine (a medicine to treat psychiatric conditions such as schizophrenia)</p><p>&nbsp;</p><p>If your doctor decides you should take these medicines with Pifeltro, one tablet of doravirine should be taken twice daily (approximately 12&nbsp;hours apart).</p><p><strong>&nbsp;</strong></p><p>Your doctor may check your blood levels or monitor for side effects if you take the following medicines with Pifeltro:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sirolimus (a medicine used to control your body&rsquo;s immune response after a transplant)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tacrolimus (a medicine used to control your body&rsquo;s immune response after a transplant)</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, talk to your doctor about the risks and benefits of taking Pifeltro. It is preferable to avoid the use of this medicine during pregnancy. This is because it has not been studied in pregnancy and it is not known if it will harm your baby while you are pregnant.</p><p>&nbsp;</p><p>Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk.</p><p><em>&nbsp;</em></p><p>If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Use caution when driving or riding a bicycle, or operating machines if you feel dizzy, tired, or sleepy after taking this medicine.</p><p>&nbsp;</p><p><strong>Pifeltro tablets contain lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to lactose, talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor, pharmacist, or nurse has told you. Check with your doctor, pharmacist, or nurse if you are not sure. This medicine must be used in combination with other medicines for HIV.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The recommended dose is 1 tablet once a day. If you take certain medicines, your doctor may need to change the amount of doravirine you take. See &ldquo;Other medicines and Pifeltro&rdquo; section for a list of medicines.</p><p>&nbsp;</p><p><strong>Taking this medicine</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet whole (do not crush or chew).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine can be taken with food or between meals.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Pifeltro than you should</strong></p><p>Do not take more than the recommended dose. If you accidentally take more, contact your doctor.</p><p><em>&nbsp;</em></p><p><strong>If you forget to take Pifeltro</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important that you do not miss or skip doses of this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take a dose, take it as soon as you remember. But if your next dose is due within 12 hours, skip the dose you missed and take the next one at the usual time. Then continue your treatment as before.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a missed dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are not sure what to do, call your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>If you stop taking Pifeltro</strong></p><p>Do not run out of this medicine. Refill your prescription or talk to your doctor before it is all gone.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Do not stop taking this medicine without first talking to your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Common</strong><strong>:</strong> may affect up to 1 in 10 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal dreams, difficulty in sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, dizziness, sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), diarrhoea, stomach pain, vomiting, wind (flatulence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired</p><p>&nbsp;</p><p>Blood tests may also show:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of liver enzymes (ALT)</p><p>&nbsp;</p><p><strong>Uncommon: </strong>may affect up to 1 in 100 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nightmares, depression, anxiety, irritability, confusion, suicidal thoughts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble concentrating, memory problems, tingling of hands and feet, stiff muscles, poor quality sleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, stomach discomfort, swollen or bloated stomach (abdominal distension), indigestion, soft stools, stomach spasms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain, joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak, general feeling of being unwell</p><p>&nbsp;</p><p>Blood tests may also show:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased levels of phosphate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of liver enzymes (AST)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of lipase</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of amylase</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased levels of haemoglobin</p><p><strong>&nbsp;</strong></p><p><strong>Rare: </strong>may affect up to 1 in 1,000 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aggression, hallucinations, difficulty adjusting to changes, mood changes, sleep walking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing, enlarged tonsils</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of incomplete defecation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin due to allergy, redness on the cheeks, nose, chin or forehead, bumps or pimples on the face</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney damage, kidney problems, kidney stones</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the chest, feeling cold, pain, thirst</p><p><strong>&nbsp;</strong></p><p>Blood tests may also show:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased levels of magnesium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of creatine phosphokinase</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor,pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA&rdquo;. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30˚C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the bottle after EXP. This medicine should be used within 35&nbsp;days after first opening of the bottle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The bottle contains a desiccant protecting the tablets from moisture. Keep the desiccant inside the bottle and do not throw away until you have finished taking all of the medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the bottle tightly closed in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is doravirine 100&nbsp;mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are croscarmellose sodium E468; hypromellose acetate succinate; lactose monohydrate; magnesium stearate E470b; microcrystalline cellulose E460; and silica, colloidal anhydrous E551. The tablets are film-coated with a coating material containing the following ingredients: carnauba wax E903; hypromellose E464; lactose monohydrate; titanium dioxide E171; and triacetin E1518.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Pifeltro is available as a white, oval-shaped, film-coated tablet, and is debossed with the corporate logo and 700 on one side and plain on the other side.

The following pack sizes are available:
•	1 bottle with 30 film-coated tablets
•	90 film-coated tablets (3 bottles of 30 film-coated tablets)

	Not all pack sizes may be available in your country.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Marketing Authorization Holder </strong></p><p>Merck Sharp &amp; Dohme B.V.</p><p>Waarderweg 39</p><p>2031 BN Haarlem</p><p>The Netherlands</p><p>&nbsp;</p><p><strong>Manufacturer</strong>:</p><p>MSD International GmbH, Kilsheelan, Clonmel, Co. Tipperary, Ireland</p><p>&nbsp;</p><p><strong>This leaflet was last revised in September </strong><strong>2022</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p><strong>This is a Medicament</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicament &nbsp;is &nbsp;a &nbsp;product &nbsp;which &nbsp;affects &nbsp;your &nbsp;health &nbsp;and &nbsp;its &nbsp;consumption &nbsp;contrary &nbsp;to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep all medicaments out of reach of children.</p><p>&nbsp;</p></td></tr></tbody></table><p>Council of Arab Health</p><p>Ministers Union of Arab Pharmacists</p><p>&nbsp;</p><p>This patient information leaflet is approved by the Saudi Food and Drug Authority</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُستخدم بفلترو لعلاج عدوى فيروس نقص المناعة البشرية (HIV). وهو ينتمي إلى مجموعة من الأدوية تُسمى &quot;الأدوية المضادة للفيروسات العكسية&quot;.</p><p dir="RTL">يحتوي بفلترو على المادة الفعّالة دورافيرين - مثبط إنزيم المُنتسِخة العكسية الغير نوكليوسيدي (NNRTI).</p><p dir="RTL"><strong>ما دواعي استخدام بفلترو</strong><br />يُستخدم بفلترو لعلاج عدوى فيروس نقص المناعة البشرية لدى &nbsp;البالغين و المراهقين من العمر 12 عامًا فما فوق و بوزن 35 كجم على الأقل. فيروس نقص المناعة البشرية هو الفيروس الذي يسبب الإيدز (&quot;متلازمة نقص المناعة المكتسب&quot;). يجب ألا تتناول بفلترو إذا أخبرك طبيبك أن الفيروس المسبب للعدوى لديك مُقاوم لدورافيرين.</p><p dir="RTL">يجب استخدام بفلترو مع أدوية أخرى مضادة لفيروس نقص المناعة البشرية.</p><p dir="RTL"><strong>ألية عمل بفلترو</strong><br />يعمل بفلترو، عند استخدامه مع الأدوية الأخرى، عن طريق منع فيروس نقص المناعة البشرية من إنتاج المزيد من الفيروسات في جسمك. سيساعد ذلك في:<br />&bull; تقليل كمية فيروس نقص المناعة البشرية في دمك (وهذا ما يسمى &quot;الحِمل الفيروسي الخاص بك&quot;)<br />&bull; زيادة عدد خلايا الدم البيضاء التي تسمى &quot;CD4<sup>+</sup> T&quot;. وهذا يمكن أن يجعل الجهاز المناعي أقوى لديك.<br />&nbsp; قد يقلل ذلك من خطر الوفاة المبكرة أو الإصابة بالعدوى الناجمة عن ضعف جهاز المناعة لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم بفلترو إذا:</strong><br />&bull; إذا كنت تعاني من حساسية تجاه دورافيرين أو أيّ من المكونات الأخرى لهذا الدواء المدرجة في الفقرة رقم&nbsp; 6.</p><p dir="RTL">&bull; إذا كنت تتناول الأدوية التالية:</p><p dir="RTL">- كاربامازيبين، أوكسكاربازيبين، الفينوباربيتال، الفينيتوين (أدوية للنوبات)</p><p dir="RTL">- ريفامبيسين، ريفابِنتين (أدوية لمرض السل)</p><p dir="RTL">- نبتة سانت جون (Hypericum perforatum، وهو علاج عشبي يستخدم لعلاج الاكتئاب والقلق) أو<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المنتجات التي تحتوي عليه.</p><p dir="RTL">- ميتوتين (دواء لعلاج السرطان)</p><p dir="RTL">- إنزالوتاميد (دواء لعلاج سرطان البروستاتا)</p><p dir="RTL">- لوماكافتور (دواء لعلاج التليف الكيسي)</p><p dir="RTL">لا تستخدم بفلترو إذا كان أيّ مما سبق ينطبق عليك. إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو الصيدلي أو الممرض قبل تناول بفلترو. أنظر أيضًا فقرة &quot;الأدوية الأخرى و بفلترو&quot;.<br />&nbsp;</p><p dir="RTL"><strong>التحذيرات والإحتياطات</strong><br />تحدث إلى طبيبك أو الصيدلي أو الممرض قبل تناول بفلترو.</p><p dir="RTL"><strong>متلازمة تنشيط المناعة</strong><br />يمكن أن يحدث هذا عند البدء في تناول أي دواء مضاد لفيروس نقص المناعة البشرية، بما في ذلك هذا الدواء. قد يصبح نظام المناعة لديك أقوى ويبدأ في مكافحة الالتهابات التي كانت مخبأة في جسمك لفترة طويلة. أخبر طبيبك على الفور إذا بدأت تواجه أي أعراض جديدة بعد البدء في تناول دواء مضاد لفيروس نقص المناعة البشرية.</p><p dir="RTL">اضطرابات المناعة الذاتية (وهي حالة تحدث عندما يهاجم الجهاز المناعي أنسجة الجسم السليمة) قد تحدث أيضًا بعد البدء في تناول الأدوية لعلاج عدوى فيروس نقص المناعة البشرية. اضطرابات المناعة الذاتية قد تحدث بعد عدة أشهر من بدء العلاج. إذا لاحظت أي أعراض للعدوى أو أعراض أخرى مثل ضعف العضلات، وضعف في اليدين والقدمين والتحرك نحو جذع الجسم، خفقان، هزة أو فرط النشاط، يرجى إبلاغ الطبيب فوراً لطلب العلاج اللازم.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong><br />لا تعطِ هذا الدواء لأي طفل يقل عمره عن 12 عامًا أو بوزن أقل من 35 كجم. لم تتم دراسة بفلترو لدى الأطفال الذين تقل أعمارهم عن 12 عامًا أو بوزن أقل من 35 كجم.</p><p dir="RTL"><strong>الأدوية الأخرى و بفلترو </strong><br />أخبر طبيبك أو الصيدلي أو الممرض إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى. وذلك لأن الأدوية الأخرى قد تؤثر على آلية عمل بفلترو، وقد يؤثر بفلترو على الطريقة التي تعمل بها بعض الأدوية الأخرى.</p><p dir="RTL">هناك بعض الأدوية التي يجب ألا تتناولها مع بفلترو. انظر القائمة تحت عنوان &quot;لا تتناول بفلترو&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك قبل تناول الأدوية التالية مع بفلترو، حيث قد يحتاج طبيبك إلى تغيير جرعة الأدوية الخاصة بك:</p><p dir="RTL">&bull; بوسنتان (دواء لعلاج أمراض الرئة)</p><p dir="RTL">&bull; دابرافينب (دواء لعلاج سرطان الجلد)</p><p dir="RTL">&bull; ليسينوراد (دواء لعلاج النقرس)</p><p dir="RTL">&bull; مودافينيل (دواء لعلاج النعاس المفرط)</p><p dir="RTL">&bull; نافسيلّين (دواء لعلاج بعض أنواع العدوى البكتيرية)</p><p dir="RTL">&bull; ريفابوتين (دواء لعلاج بعض أنواع العدوى البكتيرية مثل السل)</p><p dir="RTL">&bull; تيلوتريستات إيثيل (دواء لعلاج الإسهال لدى الأشخاص المصابين بالمتلازمة السَّرَطاوية)</p><p dir="RTL">&bull; ثيوريدازين (دواء لعلاج الأمراض النفسية مثل الفِصام)<br />&nbsp;</p><p dir="RTL">إذا قرر طبيبك أن تتناول هذه الأدوية مع بفلترو، فيجب تناول قرص من دورافيرين مرتين يوميًا (حوالي 12 ساعة تقريبًا).</p><p dir="RTL">قد يقوم طبيبك بفحص مستويات دمك أو بمراقبتك تحسبا لحدوث الأعراض الجانبية إذا كنت تتناول أيًّا من الأدوية التالية مع بفلترو:</p><p dir="RTL">&bull; سيروليمس (دواء يستخدم للتحكم في الاستجابة المناعية لجسمك بعد عملية الزرع)</p><p dir="RTL">&bull; تاكروليمس (دواء يستخدم للسيطرة على الاستجابة المناعية لجسمك بعد عملية الزرع)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">تحدثي إلى طبيبكِ حول مخاطر وفوائد تناول بفلترو إذا كنتِ حامل أو ترضعين طبيعيا أو إذا كنتِ تعتقدين أنك قد تكونين حامل أو تخططين للحمل. من الأفضل تجنب استخدام بفلترو أثناء الحمل. وذلك لأنه لم يتم دراسته أثناء الحمل وليس معروفا ما إذا كان بفلترو سيؤذي جنينك أم لا أثناء الحمل.</p><p dir="RTL">لا يُنصح بالرضاعة الطبيعية للنساء المصابات بفيروس نقص المناعة البشرية لأنّه يمكن نقل فيروس نقص المناعة البشرية إلى الأطفال من خلال حليب الثدي.</p><p dir="RTL">إذا كنت ترضعين طفلك رضاعة طبيعية، أو تفكرين في الرضاعة الطبيعية، يجب عليك مناقشة الأمر مع طبيبك في أقرب وقت ممكن.</p><p dir="RTL"><strong>&nbsp;القيادة واستخدام الآلات</strong></p><p dir="RTL">توخ الحذر عند القيادة أو ركوب الدراجة، أو تشغيل الآلات إذا شعرت بالدوار أو التعب أو النوم بعد تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أقراص بفلترو تحتوي على اللاكتوز</strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول هذا الدواء إذا سبق وأخبرك طبيب أنّ لديك عدم تحمل للّاكتوز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء دائمًا حسب إرشادات الطبيب أو الصيدلي أو الممرض. استشر طبيبك أو الصيدلي أو الممرض إذا كنت غير متأكد. يجب استخدام هذا الدواء مع أدوية أخرى مضادة لفيروس نقص المناعة البشرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كم تبلغ الجرعة</strong><br />الجرعة الموصى بها هي حبة واحدة مرة واحدة في اليوم. إذا كنت تتناول أدوية معينة، فقد يحتاج طبيبك إلى تغيير جرعة دورافيرين التي تتناولها. راجع فقرة &nbsp;&quot;الأدوية الأخرى و بفلترو&quot; للحصول على قائمة تلك الأدوية.</p><p dir="RTL"><br /><strong>طريقة تناول الدواء</strong></p><p dir="RTL">&bull; ابتلع القرص بالكامل (لا تسحقه أو تمضغه).</p><p dir="RTL">&bull; يمكن تناول هذا الدواء مع الطعام أو بين الوجبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت من بفلترو أكثر مما يجب</strong></p><p dir="RTL">لا تتناول أكثر من الجرعة الموصى بها. إذا تناولت أكثر مما يجب عن طريق الخطأ، اتصل بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول إحدى جرعات بفلترو</strong></p><p dir="RTL">&bull; من المهم ألا تفوّت أو تتخطي أيّ جرعة من هذا الدواء.</p><p dir="RTL">&bull; إذا نسيت تناول إحدى الجرعات، فتناولها حالما تتذكرها. ولكن إذا كانت الجرعة التالية مستحقة خلال 12 ساعة، فتخطى الجرعة الفائتة وتناول الجرعة التالية في الوقت المعتاد. ثم تابع علاجك كالمعتاد.</p><p dir="RTL">&bull; لا تتناول جرعة مضاعفة لتعويض جرعة فائتة.</p><p dir="RTL">&bull; إذا لم تكن متأكدًا مما يجب عليك فعله، فاتصل بطبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول</strong> <strong>بفلترو</strong></p><p dir="RTL">لا تدع هذا الدواء ينفذ منك. قم بإعادة صرف وصفتك الطبية أو تحدث إلى طبيبك قبل نفاد بيفيلترو منك.<strong> </strong>&nbsp;<br /><br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرض.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، على الرغم من أنها لا تحدث لدى جميع من يستخدمه. لا تتوقف عن تناول هذا الدواء دون التحدث أولاً مع طبيبك.</p><p dir="RTL"><strong>شائعة:</strong> قد تُؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص:</p><p dir="RTL">&bull; أحلام غير طبيعية، صعوبة في النوم (الأرق)</p><p dir="RTL">&bull; صداع، دوخة، نعاس</p><p dir="RTL">&bull; الشعور بالمرض (الغثيان) والإسهال وآلام في المعدة والقيء والغازات (انتفاخ البطن)</p><p dir="RTL">&bull; طفح جلدي</p><p dir="RTL">&bull; الشعور بالتعب</p><p dir="RTL">قد تُظهر فحوصات الدم المِخبرية أيضا:<br />&bull; زيادة مستويات أنزيمات الكبد (ALT)<br />&nbsp;</p><p dir="RTL"><strong>غير شائعة:</strong> قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص:</p><p dir="RTL">&bull; الكوابيس والاكتئاب والقلق والتهيج والارتباك والأفكار الانتحارية</p><p dir="RTL">&bull; صعوبة في التركيز، مشاكل في الذاكرة، وخز في اليدين والقدمين، وتيبّس العضلات، وتدني جودة النوم.</p><p dir="RTL">&bull; ارتفاع ضغط الدم.</p><p dir="RTL">&bull; إمساك، أو إنزعاج في المعدة، أو تورّم أو انتفاخ المعدة (انتفاخ البطن)، وعسر الهضم، والبراز الرخو،<br />&nbsp; وتشنجات المعدة.</p><p dir="RTL">&bull; الحكة</p><p dir="RTL">&bull; آلام في العضلات وآلام المفاصل<br />&bull; الشعور بالضعف والشعور العام بالتوعك</p><p dir="RTL">قد تُظهر فحوصات الدم المِخبرية أيضا:</p><p dir="RTL">&bull; انخفاض مستويات الفوسفات</p><p dir="RTL">&bull; زيادة مستويات أنزيمات الكبد (AST)</p><p dir="RTL">&bull; زيادة مستويات الليباز</p><p dir="RTL">&bull; زيادة مستويات الأميليز</p><p dir="RTL">&bull; انخفاض مستويات الهيموغلوبين<br />&nbsp;</p><p dir="RTL"><strong>نادرة:</strong> قد تُؤثر على ما يصل إلى شخص واحد من كل 1000 شخص</p><p dir="RTL">&bull; العدوانية، والهلوسة، وصعوبة التكيف مع التغيرات، وتغيرات المزاج، والمشي أثناء النوم</p><p dir="RTL">&bull; صعوبة في التنفس، تضخم اللوزتين</p><p dir="RTL">&bull; الشعور بعدم التغوط الكامل</p><p dir="RTL">&bull; التهاب الجلد بسبب الحساسية، احمرار الخدين أو الأنف أو الذقن أو الجبين، النتوءات أو البثور على<br />&nbsp; الوجه.</p><p dir="RTL">&bull; تلف الكلى، مشاكل الكلى، حصى الكلى</p><p dir="RTL">&bull; ألم في الصدر، والشعور بالبرد، والألم، والعطش</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تُظهر فحوصات الدم المِخبرية أيضا:</p><p dir="RTL">&bull; انخفاض مستويات المغنيسيوم</p><p dir="RTL">&bull; زيادة مستويات الكرياتين فسفوكيناز</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن االأعراض الجانبية</strong></p><p dir="RTL">إذا أُصبت ﺑﺄي من الأعراض الجانبية، فينبغي استشارة الطبيب أو الصيدلي أو الممرض. يشمل هذا أي أعراض جانبية ممكنة ليست مذكورة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبية عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء السعودية&quot;.</p><p dir="RTL">من خلال إبلاغك عن الأعراض الجانبية، يُمكنك المُساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية.</p><p dir="RTL">&bull; يُحفظ هذا الدواء بعيدا عن عن أنظار ومُتناول الأطفال.</p><p dir="RTL">&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء تاريخ الصلاحية المدرج على العبوة بعد كلمة EXP. يجب &nbsp;استخدام هذا الدواء في غضون 35 يومًا بعد فتح العبوة لأول مرة.</p><p dir="RTL">&bull; تحتوي العبوة على مُجفِّف (مغلف مانع الرطوبة) يحمي الأقراص من الرطوبة. قد يكون هناك أكثر من مُجفِّف واحد في العبوة. اترك المُجفِّف داخل العبوة ولا تتخلص منه حتى تنتهي من تناول الدواء بالكامل.</p><p dir="RTL">&bull; احتفظ بالعبوة مغلقة بإحكام من أجل الحماية من الرطوبة.</p><p dir="RTL">&bull; لا تتخلص من أي أدوية عن طريق مياه الصرف أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محتويات بفلترو</p><p dir="RTL">&bull; المادة الفعالة هي دورافيرين 100 ملغم.</p><p dir="RTL">&bull; المكونات الأخرى هي كروسكارميلوز الصوديوم E468؛ سَكْسِينات أسيتات هيبروميلوز، مونوهيدرات &nbsp;اللاكتوز؛ ستيرات المغنيسيوم E470b. السليلوز دقيق التبلور E460؛ سيليكا غروية لامائية E551.<br />&nbsp; الأقراص مُغلّفة بأغشية شفافة تحتوي على المكونات التالية: شمع كارنوبا &nbsp;E903؛ هيبروميلوز E464؛ مونوهيدرات اللاكتوز؛ ثاني أكسيد التيتانيوم E171 ؛ وثلاثي الأستين &nbsp;E1518.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو الشكل الصيدلاني لبفلترو ووصفه وحجم عبوته </strong></p><p dir="RTL">يتوفر بيفِترو على شكل قرص أبيض بيضاوي الشكل ومغلف بغشاء رقيق، منقوش على أحد جانبيه شعار الشركة و الرقم 700 &nbsp;و خالي من الجانب الآخر</p><p dir="RTL">تتوفر العبوات بالأحجام التالية:</p><p dir="RTL">&bull; عبوة تتكون من قارورة واحدة تحتوي على 30 قرص مغلف.</p><p dir="RTL">&bull; عبوة تتكون من 3 قوارير، في كل منها 30 قرص مغلف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في بلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق</strong></p><p dir="RTL">ميرك شارب ودوم بي. في.</p><p dir="RTL">واردرويج 39</p><p dir="RTL">٢٠٣١ بي إن هارلم</p><p dir="RTL">هولندا</p><p dir="RTL">الشركة الصّانِعة</p><p dir="RTL">شركة إم إس دي الدولية جي إم بي إتش، كيلشيلان، كلوميل، شركه تيبيراري، إيرلندا</p><p dir="RTL">تمت آخر مراجعة لهذه النشرة بتاريخ: سبتمبر 2022.</p><p dir="RTL"><strong>للإبلاغ عن أيّ أعراض جانبية:</strong></p><p dir="RTL"><strong>&bull; المملكة العربية السعودية:</strong></p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">للاتصال باالهيئة العامة للغذاء والدواء: 1999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull; دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">يرجى الاتصال بالجهة المختصة ذات الصلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>(هذا دواء)</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الدّواء مستحضر يُؤثِّر على صحتك وتناوله خِلافا للتّعليمات يُعَرِّضُك للخطر.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>اتّبع بدقة وصفة الطّبِيب وطريقة الاستعمال وتعليمات الصيدلي الذي صرف لك هذا الدّواء.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الطّبِيب والصيدلي هما الخبيران بالدّواء وبنفعه وضرره.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لا تقطع مُدّة العلاج المحُدّدة لك من تِلْقَاء نفسك.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لا تُكرِّر صرف الدّواء بدون استشارة الطّبِيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ الأدوية بعيدا عن متناول أيدي الأطفال.</p><p dir="RTL">مجلس وزراء الصِّحة العرب</p><p dir="RTL">واتِّحاد الصيادلة العرب</p><p dir="RTL">تمت الموافقة على نشرة معلومات المريض هذه من قبل الهيئة السعودية للغذاء والدواء</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر 2022.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pifeltro 100 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 100 mg of doravirine.

Excipient with known effect
Each film-coated tablet contains 222 mg lactose (as monohydrate).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet

White, oval-shaped, tablet of dimensions 19.00 mm x 9.50 mm, debossed with the corporate logo and 700 on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12&nbsp;years and older weighing at least 35&nbsp;kg infected with HIV‑1 without past or present evidence of resistance to the NNRTI class (see sections&nbsp;4.4 and&nbsp;5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be initiated by a physician experienced in the management of HIV infection.</p><p>&nbsp;</p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p>The recommended dose is one 100&nbsp;mg tablet taken orally once daily with or without food.</p><p><em>&nbsp;</em></p><p><em>Dose adjustment</em></p><p>If Pifeltro is co-administered with rifabutin, one 100&nbsp;mg tablet of Pifeltro should be taken twice daily (approximately 12&nbsp;hours apart) (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Co-administration of doravirine with other moderate CYP3A inducers has not been evaluated, but decreased doravirine concentrations are expected. If co-administration with other moderate CYP3A inducers (e.g., dabrafenib, lesinurad, bosentan, thioridazine, nafcillin, modafinil, telotristat ethyl) cannot be avoided, one 100&nbsp;mg tablet of Pifeltro should be taken twice daily (approximately 12&nbsp;hours apart).</p><p><u>&nbsp;</u></p><p><em>Missed dose</em></p><p>If the patient misses a dose of Pifeltro within 12&nbsp;hours of the time it is usually taken, the patient should take as soon as possible and resume the normal dosing schedule. If a patient misses a dose by more than 12&nbsp;hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not take 2&nbsp;doses at one time.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>No dose adjustment of doravirine is needed in elderly patients (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment of doravirine is required in patients with mild, moderate, or severe renal impairment. Doravirine has not been studied in patients with end-stage renal disease and has not been studied in dialysis patients (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of doravirine is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Doravirine has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). It is not known whether the exposure to doravirine will increase in patients with severe hepatic impairment. Therefore, caution is advised when doravirine is administered to patients with severe hepatic impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Safety and efficacy of Pifeltro in children aged less than 12&nbsp;years or weighing less than 35&nbsp;kg have not been established.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Pifeltro must be taken orally, once daily with or without food and swallowed whole (see section&nbsp;5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Co-administration with medicinal products that are strong cytochrome P450 CYP3A enzyme inducers is contraindicated as significant decreases in doravirine plasma concentrations are expected to occur, which may decrease the effectiveness of Pifeltro (see sections 4.4 and 4.5). These medicinal products include, but are not limited, to the following:
•	carbamazepine, oxcarbazepine, phenobarbital, phenytoin
•	rifampicin, rifapentine
•	St. John’s wort (Hypericum perforatum)
•	mitotane
•	enzalutamide
•	lumacaftor

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>NNRTI substitutions and use of doravirine</u></p><p>Doravirine has not been evaluated in patients with previous virologic failure to any other antiretroviral therapy. NNRTI-associated mutations detected at screening were part of exclusion criteria in the Phase 2b/3-studies. A breakpoint for a reduction in susceptibility, yielded by various NNRTI substitutions, that is associated with a reduction in clinical efficacy has not been established (see section&nbsp;5.1). There is not sufficient clinical evidence to support the use of doravirine in patients infected with HIV‑1 with evidence of resistance to the NNRTI class.</p><p>&nbsp;</p><p><u>Use with CYP3A inducers</u></p><p>Caution should be given to prescribing doravirine with medicinal products that may reduce the exposure of doravirine (see sections&nbsp;4.3 and&nbsp;4.5).</p><p><u>&nbsp;</u></p><p><u>Immune reactivation syndrome</u></p><p>Immune reactivation syndrome has been reported in patients treated with combination antiretroviral therapy. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as <em>Mycobacterium avium</em> infection, cytomegalovirus, <em>Pneumocystis jirovecii</em> pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.</p><p>&nbsp;</p><p>Autoimmune disorders (such as Graves&rsquo; disease, autoimmune hepatitis, polymyositis, and Guillain-Barr&eacute; syndrome) have also been reported to occur in the setting of immune reactivation; however, the time to onset is more variable and can occur many months after initiation of treatment.</p><p>&nbsp;</p><p><u>Lactose</u></p><p>The tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on doravirine</u></p><p>Doravirine is primarily metabolised by CYP3A, and medicinal products that induce or inhibit CYP3A are expected to affect the clearance of doravirine (see section 5.2). Doravirine should not be co-administered with medicinal products that are strong CYP3A enzyme inducers as significant decreases in doravirine plasma concentrations are expected to occur, which may decrease the effectiveness of doravirine (see sections&nbsp;4.3 and&nbsp;5.2).</p><p>&nbsp;</p><p>Co-administration with the moderate CYP3A inducer rifabutin decreased doravirine concentrations (see Table&nbsp;1). When doravirine is co-administered with rifabutin, the doravirine dose should be increased to 100&nbsp;mg twice daily (the doses should be taken approximately 12&nbsp;hours apart) (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Co-administration of doravirine with other moderate CYP3A inducers has not been evaluated, but decreased doravirine concentrations are expected. If co-administration with other moderate CYP3A inducers (e.g., dabrafenib, lesinurad, bosentan, thioridazine, nafcillin, modafinil, telotristat ethyl) cannot be avoided, the doravirine dose should be increased to 100&nbsp;mg twice daily (the doses should be taken approximately 12&nbsp;hours apart) (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Co-administration of doravirine and medicinal products that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. However, no dose adjustment is needed when doravirine is co-administered with CYP3A inhibitors.</p><p>&nbsp;</p><p><u>Effects of doravirine on other medicinal products</u></p><p>Doravirine at a dose of 100&nbsp;mg once daily is not likely to have a clinically relevant effect on the plasma concentrations of medicinal products that are dependent on transport proteins for absorption and/or elimination or that are metabolised by CYP enzymes.</p><p>&nbsp;</p><p>However, co-administration of doravirine and the sensitive CYP3A substrate midazolam resulted in a 18&nbsp;% decrease in midazolam exposure, suggesting that doravirine may be a weak CYP3A inducer. Therefore caution should be used when co-administering doravirine with medicinal products that are sensitive CYP3A substrates that also have a narrow therapeutic window (e.g., tacrolimus and sirolimus).</p><p><u>&nbsp;</u></p><p><u>Interactions table</u></p><p>Table 1 shows the established and other potential medicinal product interactions with doravirine but is not all inclusive (increase is indicated as &shy;, decrease is indicated as &darr;, and no change as &harr;).</p><p>&nbsp;</p><p><strong>Table 1: </strong><strong>Interactions of </strong><strong>doravirine</strong><strong> with other medicinal products</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:103%"><thead><tr><td style="vertical-align:top"><p><strong>Medicinal Product by Therapeutic Area</strong></p></td><td><p><strong>Effects on Medicinal Product Levels Geometric Mean Ratio (90&nbsp;% CI)</strong>*</p></td><td style="vertical-align:top"><p><strong>Recommendation Concerning Co-administration with doravirine</strong></p></td></tr></thead><tbody><tr><td colspan="3"><p>Acid-Reducing Agents</p></td></tr><tr><td><p>antacid (aluminium and magnesium hydroxide oral suspension)</p><p>(20&nbsp;mL SD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td style="vertical-align:top"><p>&laquo; doravirine</p><p>AUC 1.01 (0.92, 1.11)</p><p>C<sub>max</sub> 0.86 (0.74, 1.01)</p><p>C<sub>24</sub> 1.03 (0.94, 1.12)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>pantoprazole</p><p>(40&nbsp;mg QD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td style="vertical-align:top"><p>&macr; doravirine</p><p>AUC 0.83 (0.76, 0.91)</p><p>C<sub>max</sub> 0.88 (0.76, 1.01)</p><p>C<sub>24</sub> 0.84 (0.77, 0.92)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>omeprazole</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Angiotensin Converting Enzyme Inhibitors</p></td></tr><tr><td><p>lisinopril</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&harr; lisinopril</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Antiandrogens</p></td></tr><tr><td><p>enzalutamide</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Antibiotics</p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td><p>nafcillin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, one tablet of doravirine should be taken twice daily (approximately 12&nbsp;hours apart).</p></td></tr><tr><td colspan="3"><p>Anticonvulsants</p></td></tr><tr><td><p>carbamazepine</p><p>oxcarbazepine</p><p>phenobarbital</p><p>phenytoin</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3"><p>Antidiabetics</p></td></tr><tr><td><p>metformin</p><p>(1000&nbsp;mg SD,</p><p>doravirine 100&nbsp;mg QD)</p></td><td style="vertical-align:top"><p>&laquo; metformin</p><p>AUC 0.94 (0.88, 1.00)</p><p>C<sub>max</sub> 0.94 (0.86, 1.03)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>canagliflozin</p><p>liraglutide</p><p>sitagliptin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&harr; canagliflozin</p><p>&harr; liraglutide</p><p>&harr; sitagliptin</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Antidiarrhoeals</p></td></tr><tr><td><p>telotristat ethyl</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, one tablet of doravirine should be taken twice daily (approximately 12&nbsp;hours apart).</p></td></tr><tr><td colspan="3"><p>Antigout and Uricosuric Agents</p></td></tr><tr><td><p>lesinurad</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, one tablet of doravirine should be taken twice daily (approximately 12&nbsp;hours apart).</p></td></tr><tr><td colspan="3"><p>Antimycobacterials</p></td></tr><tr><td style="vertical-align:top"><p>Single dose rifampicin</p><p>(600&nbsp;mg SD,</p><p>doravirine 100&nbsp;mg SD)</p><p>&nbsp;</p><p>&nbsp;</p><p>Multiple dose rifampicin</p><p>(600&nbsp;mg QD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td style="vertical-align:top"><p>&laquo; doravirine</p><p>AUC 0.91 (0.78, 1.06)</p><p>C<sub>max</sub> 1.40 (1.21, 1.63)</p><p>C<sub>24</sub> 0.90 (0.80, 1.01)</p><p>&nbsp;</p><p>&macr; doravirine</p><p>AUC 0.12 (0.10, 0.15)</p><p>C<sub>max</sub> 0.43 (0.35, 0.52)</p><p>C<sub>24</sub> 0.03 (0.02, 0.04)</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td><p>rifapentine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td><p>rifabutin</p><p>(300&nbsp;mg QD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td style="vertical-align:top"><p>&macr; doravirine</p><p>AUC 0.50 (0.45, 0.55)</p><p>C<sub>max</sub> 0.99 (0.85, 1.15)</p><p>C<sub>24</sub> 0.32 (0.28, 0.35)</p><p>(Induction of CYP3A)</p></td><td><p>If doravirine is co-administered with rifabutin, the doravirine dose should be increased to 100&nbsp;mg twice daily (approximately 12&nbsp;hours apart).</p></td></tr><tr><td colspan="3"><p>Antineoplastics</p></td></tr><tr><td><p>mitotane</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3"><p>Antipsychotics</p></td></tr><tr><td><p>thioridazine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, one tablet of doravirine should be taken twice daily (approximately 12&nbsp;hours apart).</p></td></tr><tr><td colspan="3"><p>Azole Antifungal Agents</p></td></tr><tr><td><p>ketoconazole</p><p>(400&nbsp;mg QD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td style="vertical-align:top"><p>&shy; doravirine</p><p>AUC 3.06 (2.85, 3.29)</p><p>C<sub>max</sub> 1.25 (1.05, 1.49)</p><p>C<sub>24</sub> 2.75 (2.54, 2.98)</p><p>(Inhibition of CYP3A)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>fluconazole</p><p>itraconazole</p><p>posaconazole</p><p>voriconazole</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(Inhibition of CYP3A4)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Calcium Channel Blockers</p></td></tr><tr><td><p>diltiazem</p><p>verapamil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(CYP3A inhibition)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Cystic Fibrosis Treatment</p></td></tr><tr><td><p>lumacaftor</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3"><p>Endothelin Receptor Antagonists</p></td></tr><tr><td><p>bosentan</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, one tablet of doravirine should be taken twice daily (approximately 12&nbsp;hours apart).</p></td></tr><tr><td colspan="3"><p>Hepatitis C Antiviral Agents</p></td></tr><tr><td><p>elbasvir + grazoprevir</p><p>(50&nbsp;mg elbasvir QD + 200&nbsp;mg grazoprevir QD,</p><p>doravirine 100&nbsp;mg QD)</p></td><td style="vertical-align:top"><p>&shy; doravirine</p><p>AUC 1.56 (1.45, 1.68)</p><p>C<sub>max</sub> 1.41 (1.25, 1.58)</p><p>C<sub>24</sub> 1.61 (1.45, 1.79)</p><p>(Inhibition of CYP3A)</p><p>&nbsp;</p><p>&laquo; elbasvir</p><p>AUC 0.96 (0.90, 1.02)</p><p>C<sub>max</sub> 0.96 (0.91, 1.01)</p><p>C<sub>24</sub> 0.96 (0.89, 1.04)</p><p>&nbsp;</p><p>&laquo; grazoprevir</p><p>AUC 1.07 (0.94, 1.23)</p><p>C<sub>max</sub> 1.22 (1.01, 1.47)</p><p>C<sub>24</sub> 0.90 (0.83, 0.96)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>ledipasvir + sofosbuvir</p><p>(90&nbsp;mg ledipasvir SD + 400&nbsp;mg sofosbuvir SD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td style="vertical-align:top"><p>&shy; doravirine</p><p>AUC 1.15 (1.07, 1.24)</p><p>C<sub>max</sub> 1.11 (0.97, 1.27)</p><p>C<sub>24</sub> 1.24 (1.13, 1.36)</p><p>&nbsp;</p><p>&laquo; ledipasvir</p><p>AUC 0.92 (0.80, 1.06)</p><p>C<sub>max</sub> 0.91 (0.80, 1.02)</p><p>&nbsp;</p><p>&laquo; sofosbuvir</p><p>AUC 1.04 (0.91, 1.18)</p><p>C<sub>max</sub> 0.89 (0.79, 1.00)</p><p>&nbsp;</p><p>&laquo; GS-331007</p><p>AUC 1.03 (0.98, 1.09)</p><p>C<sub>max</sub> 1.03 (0.97, 1.09)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>sofosbuvir/velpatasvir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>sofosbuvir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>daclatasvir</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&harr; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>ombitasvir/ paritaprevir/ritonavir and dasabuvir+/-ritonavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(Inhibition of CYP3A due to ritonavir)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>dasabuvir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&laquo; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>glecaprevir, pibrentasvir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(inhibition of CYP3A)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>ribavirin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Herbal Supplements</p></td></tr><tr><td><p>St. John&rsquo;s wort</p><p>(<em>Hypericum perforatum</em>)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&macr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration is contraindicated.</p></td></tr><tr><td colspan="3"><p>HIV Antiviral Agents</p></td></tr><tr><td colspan="3"><p>Fusion and Entry Inhibitors</p></td></tr><tr><td><p>enfuvirtide</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&harr; doravirine</p><p>&harr; enfuviritide</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>maraviroc</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&harr; doravirine</p><p>&harr; maraviroc</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Protease Inhibitors</p></td></tr><tr><td><p>ritonavir<sup>&dagger;</sup>- boosted PIs</p><p>(atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, saquinavir, tipranavir)</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(Inhibition of CYP3A)</p><p>&nbsp;</p><p>&harr; boosted PIs</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>cobicistat-boosted PIs</p><p>(darunavir, atazanavir)</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(Inhibition of CYP3A)</p><p>&nbsp;</p><p>&harr; boosted PIs</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Integrase Strand Transfer Inhibitors</p></td></tr><tr><td><p>dolutegravir</p><p>(50&nbsp;mg QD,</p><p>doravirine 200&nbsp;mg QD)</p></td><td style="vertical-align:top"><p>&laquo; doravirine</p><p>AUC 1.00 (0.89, 1.12)</p><p>C<sub>max</sub> 1.06 (0.88, 1.28)</p><p>C<sub>24</sub> 0.98 (0.88, 1.09)</p><p>&nbsp;</p><p>&shy; dolutegravir</p><p>AUC 1.36 (1.15, 1.62)</p><p>C<sub>max</sub> 1.43 (1.20, 1.71)</p><p>C<sub>24</sub> 1.27 (1.06, 1.53)</p><p>(Inhibition of BCRP)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>raltegravir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&harr; doravirine</p><p>&harr; raltegravir</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>ritonavir<sup>&dagger;</sup>-boosted elvitegravir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(CYP3A inhibition)</p><p>&nbsp;</p><p>&harr; elvitegravir</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>cobicistat-boosted elvitegravir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(CYP3A inhibition)</p><p>&harr; elvitegravir</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Nucleoside Reverse Transcriptase Inhibitors</p></td></tr><tr><td><p>tenofovir disoproxil</p><p>(245&nbsp;mg QD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td style="vertical-align:top"><p>&laquo; doravirine</p><p>AUC 0.95 (0.80, 1.12)</p><p>C<sub>max</sub> 0.80 (0.64, 1.01)</p><p>C<sub>24</sub> 0.94 (0.78, 1.12)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>lamivudine + tenofovir disoproxil</p><p>(300&nbsp;mg lamivudine SD + 245&nbsp;mg tenofovir disoproxil SD,</p><p>doravirine 100&nbsp;mg SD)</p></td><td style="vertical-align:top"><p>&laquo; doravirine</p><p>AUC 0.96 (0.87, 1.06)</p><p>C<sub>max</sub> 0.97 (0.88, 1.07)</p><p>C<sub>24</sub> 0.94 (0.83, 1.06)</p><p>&nbsp;</p><p>&laquo; lamivudine</p><p>AUC 0.94 (0.88, 1.00)</p><p>C<sub>max</sub> 0.92 (0.81, 1.05)</p><p>&nbsp;</p><p>&laquo; tenofovir</p><p>AUC 1.11 (0.97, 1.28)</p><p>C<sub>max</sub> 1.17 (0.96, 1.42)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td style="vertical-align:top"><p>abacavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&harr; doravirine</p><p>&harr; abacavir</p></td><td style="vertical-align:top"><p>No dose adjustment is required.</p></td></tr><tr><td><p>emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&harr; doravirine</p><p>&harr; emtricitabine</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>tenofovir alafenamide</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&harr; doravirine</p><p>&harr; tenofovir alafenamide</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Immunosuppressants</p></td></tr><tr><td><p>tacrolimus</p><p>sirolimus</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; doravirine</p><p>&darr; tacrolimus, sirolimus</p><p>(Induction of CYP3A)</p></td><td><p>Monitor blood concentrations of tacrolimus and sirolimus as the dose of these agents may need to be adjusted.</p><p>&nbsp;</p></td></tr><tr><td colspan="3"><p>Kinase Inhibitors</p></td></tr><tr><td><p>dabrafenib</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&darr; doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, one tablet of doravirine should be taken twice daily (approximately 12&nbsp;hours apart).</p></td></tr><tr><td colspan="3"><p>Opioid Analgesics</p></td></tr><tr><td><p>methadone</p><p>20-200&nbsp;mg QD individualised dose,</p><p>doravirine 100&nbsp;mg QD</p></td><td style="vertical-align:top"><p>&macr; doravirine</p><p>AUC 0.74 (0.61, 0.90)</p><p>C<sub>max</sub> 0.76 (0.63, 0.91)</p><p>C<sub>24</sub> 0.80 (0.63, 1.03)</p><p>&nbsp;</p><p>&laquo; R-methadone</p><p>AUC 0.95 (0.90, 1.01)</p><p>C<sub>max</sub> 0.98 (0.93, 1.03)</p><p>C<sub>24</sub> 0.95 (0.88, 1.03)</p><p>&nbsp;</p><p>&laquo; S-methadone</p><p>AUC 0.98 (0.90, 1.06)</p><p>C<sub>max</sub> 0.97 (0.91, 1.04)</p><p>C<sub>24</sub> 0.97 (0.86, 1.10)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>buprenorphine</p><p>naloxone</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&harr; buprenorphine</p><p>&harr; naloxone</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Oral Contraceptives</p></td></tr><tr><td style="vertical-align:top"><p>0.03&nbsp;mg ethinyl oestradiol/ 0.15&nbsp;mg levonorgestrel SD,</p><p>doravirine 100&nbsp;mg QD</p></td><td style="vertical-align:top"><p>&laquo; ethinyl oestradiol</p><p>AUC 0.98 (0.94, 1.03)</p><p>C<sub>max</sub> 0.83 (0.80, 0.87)</p><p>&nbsp;</p><p>&shy; levonorgestrel</p><p>AUC 1.21 (1.14, 1.28)</p><p>C<sub>max</sub> 0.96 (0.88, 1.05)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>norgestimate/ethinyl oestradiol</p></td><td><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&laquo; norgestimate/ethinyl oestradiol</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Pharmacokinetic Enhancers</p></td></tr><tr><td><p>ritonavir</p><p>(100&nbsp;mg BID,</p><p>doravirine 50&nbsp;mg SD)</p></td><td style="vertical-align:top"><p>&shy; doravirine</p><p>AUC 3.54 (3.04, 4.11)</p><p>C<sub>max</sub> 1.31 (1.17, 1.46)</p><p>C<sub>24</sub> 2.91 (2.33, 3.62)</p><p>(Inhibition of CYP3A)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>cobicistat</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&shy; doravirine</p><p>(Inhibition of CYP3A)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Psychostimulants</p></td></tr><tr><td><p>modafinil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Expected:</p><p>&darr;doravirine</p><p>(Induction of CYP3A)</p></td><td><p>Co-administration should be avoided. If co-administration cannot be avoided, one tablet of doravirine should be taken twice daily (approximately 12&nbsp;hours apart).</p></td></tr><tr><td colspan="3"><p>Sedatives/Hypnotics</p></td></tr><tr><td><p>midazolam</p><p>(2&nbsp;mg SD,</p><p>doravirine 120&nbsp;mg QD)</p></td><td style="vertical-align:top"><p>&macr; midazolam</p><p>AUC 0.82 (0.70, 0.97)</p><p>C<sub>max</sub> 1.02 (0.81, 1.28)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3"><p>Statins</p></td></tr><tr><td><p>atorvastatin</p><p>(20&nbsp;mg SD,</p><p>doravirine 100&nbsp;mg QD)</p></td><td style="vertical-align:top"><p>&laquo; atorvastatin</p><p>AUC 0.98 (0.90, 1.06)</p><p>C<sub>max</sub> 0.67 (0.52, 0.85)</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td><p>rosuvastatin</p><p>simvastatin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&harr; rosuvastatin</p><p>&harr; simvastatin</p></td><td><p>No dose adjustment is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&shy; = increase, &darr; = decrease, &harr; = no change</p><p>CI = Confidence Interval; SD = Single Dose; QD = Once Daily; BID = Twice Daily</p><p>*AUC<sub>0-</sub><sub>&yen;</sub> for single dose, AUC<sub>0-24</sub> for once daily.</p><p><sup>&dagger;</sup>The interaction was evaluated with ritonavir only.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no or limited amount of data from the use of doravirine in pregnant women.</p><p>&nbsp;</p><p><em>Antiretroviral pregnancy registry</em></p><p>To monitor maternal-foetal outcomes in patients exposed to antiretroviral medicinal products while pregnant, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients in this registry.</p><p>&nbsp;</p><p>Animal studies with doravirine do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>As a precautionary measure, it is preferable to avoid the use of doravirine during pregnancy.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>It is unknown whether doravirine is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of doravirine in milk (see section&nbsp;5.3).</p><p>&nbsp;</p><p>It is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission of HIV.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>No human data on the effect of doravirine on fertility are available. Animal studies do not indicate harmful effects of doravirine on fertility at exposure levels higher than the exposure in humans at the recommended clinical dose (see section&nbsp;5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pifeltro may have a minor influence on the ability to drive or use machines. Patients should be informed that fatigue, dizziness, and somnolence have been reported during treatment with doravirine (see section&nbsp;4.8). This should be considered when assessing a patient&#39;s ability to drive or operate machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most frequently reported adverse reactions considered possibly or probably related to doravirine were nausea (4&nbsp;%) and headache (3&nbsp;%).</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions </u></p><p>The adverse reactions with suspected (at least possible) relationship to treatment are listed below by body system organ class and frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100) or rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000).</p><p><strong>&nbsp;</strong></p><p><strong>Table 2: Tabulated summary of adverse reactions associated with doravirine used in combination with other antiretrovirals</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td><p><strong>Frequency</strong></p></td><td colspan="2"><p><strong>Adverse reactions</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>rash pustular</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>hypophosphataemia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>hypomagnesaemia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>abnormal dreams, insomnia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>nightmare, depression<sup>2</sup>, anxiety<sup>3</sup>, irritability, confusional state, suicidal ideation</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>aggression, hallucination, adjustment disorder, mood altered, somnambulism</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>headache, dizziness, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>disturbance in attention, memory impairment, paraesthesia, hypertonia, poor quality sleep</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>hypertension</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>dyspnoea, tonsillar hypertrophy</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>nausea, diarrhoea, flatulence, abdominal pain<sup>4</sup>, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>constipation, abdominal discomfort<sup>5</sup>, abdominal distension, dyspepsia, faeces soft<sup>6</sup>, gastrointestinal motility disorder<sup>7</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>rectal tenesmus</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>rash<sup>8</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>dermatitis allergic, rosacea</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>myalgia, arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>musculoskeletal pain</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>acute kidney injury, renal disorder, calculus urinary, nephrolithiasis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>asthenia, malaise</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>chest pain, chills, pain, thirst</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>alanine aminotransferase increased<sup>9</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>lipase increased, aspartate aminotransferase increased, amylase increased, haemoglobin decreased</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>blood creatine phosphokinase increased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>insomnia includes: insomnia, initial insomnia and sleep disorder</p><p><sup>2</sup>depression includes: depression, depressed mood, major depression, and persistent depressive disorder</p><p><sup>3</sup>anxiety includes: anxiety and generalised anxiety disorder</p><p><sup>4</sup>abdominal pain includes: abdominal pain, and abdominal pain upper</p><p><sup>5</sup>abdominal discomfort includes: abdominal discomfort, and epigastric discomfort</p><p><sup>6</sup>faeces soft includes: faeces soft and abnormal faeces</p><p><sup>7</sup>gastrointestinal motility disorder includes: gastrointestinal motility disorder, and frequent bowel movements</p><p><sup>8</sup>rash includes: rash, rash macular, rash erythematous, rash generalised, rash maculo-papular, rash papular, and urticarial</p><p><sup>9</sup>alanine aminotransferase increased<sup> </sup>includes: alanine aminotransferase increased<sup> </sup>and<sup> </sup>hepatocellular injury</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><u>Immune reactivation syndrome</u></p><p>In HIV‑infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety of doravirine as a component of doravirine/lamivudine/tenofovir disoproxil was evaluated in 45 HIV-1 infected virologically suppressed or treatment-na&iuml;ve paediatric patients 12&nbsp;to less than 18&nbsp;years of age through Week&nbsp;48 in an open-label trial (IMPAACT 2014 (Protocol&nbsp;027)). The safety profile in paediatric subjects was similar to that in adults.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no information on potential acute symptoms and signs of overdose with doravirine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Antivirals for systemic use, ATC code: J05AG06</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor of HIV‑1 and inhibits HIV‑1 replication by non-competitive inhibition of HIV‑1 reverse transcriptase (RT). Doravirine does not inhibit the human cellular DNA polymerases &alpha;, &szlig;, and mitochondrial DNA polymerase &gamma;.</p><p>&nbsp;</p><p><u>Antiviral activity in cell culture</u></p><p>Doravirine exhibited an EC<sub>50</sub> value of 12.0&plusmn;4.4&nbsp;nM against wild-type laboratory strains of HIV‑1 when tested in the presence of 100&nbsp;% normal human serum using MT4-GFP reporter cells. Doravirine demonstrated antiviral activity against a broad panel of primary HIV‑1 isolates (A, A1, AE, AG, B, BF, C, D, G, H) with EC<sub>50</sub> values ranging from 1.2&nbsp;nM to 10.0&nbsp;nM.</p><p>&nbsp;</p><p><u>Antiviral activity in combination with other HIV antiviral medicinal products</u></p><p>The antiviral activity of doravirine was not antagonistic when combined with the NNRTIs delavirdine, efavirenz, etravirine, nevirapine, or rilpivirine; the NRTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil, or zidovudine; the PIs darunavir or indinavir; the fusion inhibitor enfuvirtide; the CCR5 co-receptor antagonist maraviroc; or the integrase strand transfer inhibitor raltegravir.</p><p>&nbsp;</p><p><u>Resistance</u></p><p><em>In cell culture</em></p><p>Doravirine-resistant strains were selected in cell culture starting from wild-type HIV‑1 of different origins and subtypes, as well as NNRTI-resistant HIV‑1. Observed emergent amino acid substitutions in RT included: V106A, V106M, V106I, V108I, F227L, F227C, F227I, F227V, H221Y, M230I, L234I, P236L, and Y318F. The V106A, V106M, V108I, H221Y, F227C, M230I, P236L, and Y318F substitutions conferred 3.4-fold to 70-fold reductions in susceptibility to doravirine. Y318F in combination with V106A, V106M, V108I, and F227C conferred greater decreases in susceptibility to doravirine than Y318F alone, which conferred a 10-fold reduction in susceptibility to doravirine. Common NNRTI-resistant mutations (K103N, Y181C) were not selected in the <em>in&nbsp;vitro</em> study. V106A (yielding a fold change of around 19) appeared as an initial substitution in subtype B virus, and V106A or M in subtype A and C virus. Subsequently F227(L/C/V) or L234I emerged in addition to V106 substitution (double mutants yielding a fold change of &gt;&nbsp;100).</p><p>&nbsp;</p><p><em>In clinical trials</em></p><p><em>Treatment-na&iuml;ve adult subjects</em></p><p>The Phase 3 studies, DRIVE-FORWARD and DRIVE-AHEAD, included previously untreated patients (n = 747) where the following NNRTI substitutions were part of exclusion criteria: L100I, K101E, K101P, K103N, K103S, V106A, V106I, V106M, V108I, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, Y188C, Y188H, Y188L, G190A, G190S, H221Y, L234I, M230I, M230L, P225H, F227C, F227L, F227V.</p><p>&nbsp;</p><p>The following de novo resistance was seen in the resistance analysis subset (subjects with HIV‑1 RNA greater than 400&nbsp;copies per mL at virologic failure or early study discontinuation and having resistance data).</p><p>&nbsp;</p><p><strong>Table 3: Resistance development up to week 96 in protocol defined virologic failure population + early discontinuation population</strong><br />&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p>DRIVE-FORWARD</p></td><td colspan="2" style="vertical-align:top"><p>DRIVE-AHEAD</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>DOR +</p><p>NRTIs*</p><p>(383)</p></td><td style="vertical-align:top"><p>DRV + r +</p><p>NRTIs*</p><p>(383)</p></td><td style="vertical-align:top"><p>DOR/TDF/3TC<br />(364)</p></td><td style="vertical-align:top"><p>EFV/TDF/FTC<br />(364)</p></td></tr><tr><td style="vertical-align:top"><p>Successful genotype, n</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>33</p></td></tr><tr><td style="vertical-align:top"><p>Genotypic resistance to</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>DOR or control (DRV or EFV)</p></td><td style="vertical-align:top"><p>2 (DOR)</p></td><td style="vertical-align:top"><p>0 (DRV)</p></td><td style="vertical-align:top"><p>8 (DOR)</p></td><td style="vertical-align:top"><p>14 (EFV)</p></td></tr><tr><td style="vertical-align:top"><p>NRTI backbone</p><p>M184I/V only</p><p>K65R only</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; K65R + M184I/V</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2<sup>**</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p></td><td style="vertical-align:top"><p>0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p></td><td style="vertical-align:top"><p>6</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p></td><td style="vertical-align:top"><p>5</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*NRTIs in DOR arm: FTC/TDF (333) or ABC/3TC (50); NRTIs in DRV+r arm: FTC/TDF (335) or ABC/3TC (48)</p><p>**Subjects received FTC/TDF</p><p>ABC=abacavir; FTC=emtricitabine; DRV=darunavir; r=ritonavir</p></td></tr></tbody></table><p>&nbsp;</p><p>Emergent doravirine associated resistance substitutions in RT included one or more of the following: A98G, V106I, V106A, V106M/T, Y188L, H221Y, P225H, F227C, F227C/R, and Y318Y/F.</p><p><em>&nbsp;</em></p><p><em>Virologically suppressed adult subjects</em></p><p>The DRIVE-SHIFT study included virologically suppressed patients (N=670) with no history of treatment failure (see section, Clinical experience). A documented absence of genotypic resistance (prior to starting first therapy) to doravirine, lamivudine, and tenofovir was part of the inclusion criteria for patients who switched from a PI- or INI-based regimen.&nbsp; Exclusionary NNRTI substitutions were those listed above (DRIVE-FORWARD and DRIVE-AHEAD), with the exception of substitutions RT K103N, G190A and Y181C (accepted in DRIVE-SHIFT). &nbsp;Documentation of pre-treatment resistance genotyping was not required for patients who switched from a NNRTI-based regimen.</p><p><em>&nbsp;</em></p><p>In the DRIVE-SHIFT clinical trial, no subjects developed genotypic or phenotypic resistance to DOR, 3TC, or TDF during the initial 48 weeks (immediate switch, N=447) or 24 weeks (delayed switch, N=209) of treatment with DOR/3TC/TDF.&nbsp; One subject developed RT M184M/I mutation and phenotypic resistance to 3TC and FTC during treatment with their baseline regimen.&nbsp; None of the 24&nbsp;subjects (11 in the immediate switch group, 13 in the delayed switch group) with baseline NNRTI mutations (RT K103N, G190A, or Y181C) experienced virologic failure through Week&nbsp;48, or at time of discontinuation.</p><p>&nbsp;</p><p><em>Paediatric subjects</em></p><p>In the IMPAACT&nbsp;2014 (Protocol&nbsp;027) clinical trial, no subject who was virologically suppressed at baseline met the criteria for resistance analysis. One treatment-na&iuml;ve subject who met the protocol‑defined virologic failure criteria (defined as 2 consecutive plasma HIV-1 RNA test results &ge;200&nbsp;copies/mL) at or after Week&nbsp;24 was evaluated for the development of resistance; no emergence of genotypic or phenotypic resistance to doravirine was detected.</p><p>&nbsp;</p><p><u>Cross-resistance</u></p><p><u>&nbsp;</u></p><p>Doravirine has been evaluated in a limited number of patients with NNRTI resistance (K103N n=7, G190A n=1); all patients were suppressed to &lt;&nbsp;40 copies/mL at week 48. A breakpoint for a reduction in susceptibility, yielded by various NNRTI substitutions, that is associated with a reduction in clinical efficacy has not been established.</p><p>&nbsp;</p><p>Laboratory strains of HIV‑1 harbouring the common NNRTI-associated mutations K103N, Y181C, or K103N/Y181C substitutions in RT exhibit less than a 3-fold decrease in susceptibility to doravirine compared to wild-type virus when evaluated in the presence of 100&nbsp;% normal human serum. In <em>in&nbsp;vitro</em> studies, doravirine was able to suppress the following NNRTI-associated substitutions; K103N, Y181C, and G190A under clinically relevant concentrations.</p><p>&nbsp;</p><p>A panel of 96 diverse clinical isolates containing NNRTI-associated mutations was evaluated for susceptibility to doravirine in the presence of 10&nbsp;% foetal bovine serum. Clinical isolates containing the Y188L substitution or V106 substitutions in combination with A98G, H221Y, P225H, F227C or Y318F showed a greater than 100-fold reduced susceptibility to doravirine. Other established NNRTI substitutions yielded a fold change of 5-10 (G190S (5.7), K103N/P225H (7.9), V108I/Y181C (6.9), Y181V (5.1)). The clinical relevance of a 5-10&nbsp;fold reduction in susceptibility is unknown.</p><p>&nbsp;</p><p>Treatment emergent doravirine resistance associated substitutions may confer cross-resistance to efavirenz, rilpivirine, nevirapine, and etravirine. Of the 8 subjects who developed high level doravirine resistance in the pivotal studies, 6 had phenotypic resistance to EFV and nevirapine, 3 to rilpivirine, and 3 had partial resistance to etravirine based on the Monogram Phenosense assay.</p><p>&nbsp;</p><p><u>Clinical experience</u></p><p><em>&nbsp;</em></p><p><em>Treatment-na&iuml;ve adult subjects</em></p><p>The efficacy of doravirine is based on the analyses of 96-week data from two randomised, multicentre, double-blind, active controlled Phase 3 trials, (DRIVE-FORWARD and DRIVE‑AHEAD) in antiretroviral treatment-na&iuml;ve, HIV‑1 infected subjects (n = 1494). Refer to Resistance section for NNRTI substitutions that were part of exclusion criteria.</p><p>&nbsp;</p><p>In DRIVE-FORWARD, 766&nbsp;subjects were randomised and received at least 1 dose of either doravirine 100&nbsp;mg or darunavir + ritonavir 800+100&nbsp;mg once daily, each in combination with emtricitabine/tenofovir disoproxil (FTC/TDF) or abacavir/lamivudine (ABC/3TC) selected by the investigator. At baseline, the median age of subjects was 33&nbsp;years (range 18 to 69&nbsp;years), 86&nbsp;% had CD4<sup>+</sup> T cell count greater than 200&nbsp;cells per mm<sup>3</sup>, 84&nbsp;% were male, 27&nbsp;% were non-white, 4&nbsp;% had hepatitis B and/or C virus co-infection, 10&nbsp;% had a history of AIDS, 20&nbsp;% had HIV‑1 RNA greater than 100,000&nbsp;copies per mL, 13&nbsp;% received ABC/3TC and 87&nbsp;% received FTC/TDF; these characteristics were similar between treatment groups.</p><p>&nbsp;</p><p>In DRIVE-AHEAD, 728&nbsp;subjects were randomised and received at least 1 dose of either doravirine/lamivudine/tenofovir disoproxil 100/300/245&nbsp;mg (DOR/3TC/TDF) or efavirenz/emtricitabine/tenofovir disoproxil (EFV/FTC/TDF) once daily. At baseline, the median age of subjects was 31&nbsp;years (range 18‑70&nbsp;years), 85&nbsp;% were male, 52&nbsp;% were non-white, 3% had hepatitis B or C co-infection, 14&nbsp;% had a history of AIDS, 21&nbsp;% had HIV‑1 RNA &gt;&nbsp;100,000 copies per mL, and 12&nbsp;% had CD4<sup>+ </sup>T cell count &lt;&nbsp;200 cells per mm<sup>3</sup>; these characteristics were similar between treatment groups.</p><p>&nbsp;</p><p>Week&nbsp;48 and 96 outcomes for DRIVE-FORWARD and DRIVE-AHEAD are provided in Table&nbsp;4. The doravirine-based regimens demonstrated consistent efficacy across demographic and baseline prognostic factors.</p><p>&nbsp;</p><p><strong>Table 4: </strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-ansi-language:EN-US'><span style='mso-element:field-begin;mso-field-lock:
yes'></span><span style='mso-spacerun:yes'> </span>INCLUDETEXT
&quot;\\\\bardsar-prod\\mk1439a-hiv\\prot021-wk48-sdtm313\\outtable\\ef0vlout0w48.rtf&quot;
\c MSRTF<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>Efficacy response (&lt;&nbsp;40 copies/mL, Snapshot approach) in the pivotal studies</strong><!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;display:none;mso-hide:all'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p><strong>DRIVE-FORWARD</strong></p></td><td colspan="2"><p><strong>DRIVE-AHEAD</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>DOR + 2 NRTIs (383)</strong></p></td><td style="vertical-align:top"><p><strong>DRV + r + 2 NRTIs (383)</strong></p></td><td style="vertical-align:top"><p><strong>DOR/3TC/TDF</strong></p><p><strong>(364)</strong></p></td><td style="vertical-align:top"><p><strong>EFV/FTC/TDF</strong></p><p><strong>(364)</strong></p></td></tr><tr><td><p>Week&nbsp;48</p></td><td><p>83&nbsp;%</p></td><td><p>79&nbsp;%</p></td><td><p>84&nbsp;%</p></td><td><p>80&nbsp;%</p></td></tr><tr><td><p>Difference (95&nbsp;% CI)</p></td><td colspan="2"><p>4.2&nbsp;% (-1.4%, 9.7&nbsp;%)</p></td><td colspan="2"><p>4.1&nbsp;% (-1.5&nbsp;%, 9.7&nbsp;%)</p></td></tr><tr><td><p>Week&nbsp;96*</p></td><td><p>72&nbsp;% (N=379)</p></td><td><p>64&nbsp;% (N=376)</p></td><td><p>76&nbsp;% (N=364)</p></td><td><p>73&nbsp;% (N=364)</p></td></tr><tr><td><p>Difference (95&nbsp;% CI)</p></td><td colspan="2"><p>7.6&nbsp;% (1.0&nbsp;%, 14.2&nbsp;%)</p></td><td colspan="2"><p>3.3&nbsp;% (-3.1&nbsp;%, 9.6&nbsp;%)</p></td></tr><tr><td colspan="5"><p><strong>Week&nbsp;48 outcome (&lt;&nbsp;40 copies/mL) by baseline factors</strong></p></td></tr><tr><td colspan="5"><p>HIV‑1 RNA copies/mL</p></td></tr><tr><td><p>&le;&nbsp;100,000</p></td><td><p>256/285 (90&nbsp;%)</p></td><td><p>248/282 (88&nbsp;%)</p></td><td><p>251/277 (91&nbsp;%)</p></td><td><p>234/258 (91&nbsp;%)</p></td></tr><tr><td><p>&gt;&nbsp;100,000&nbsp;</p></td><td><p>63/79 (80&nbsp;%)</p></td><td><p>54/72 (75&nbsp;%)</p></td><td><p>54/69 (78 %)</p></td><td><p>56/73 (77&nbsp;%)</p></td></tr><tr><td colspan="5"><p>CD4 count, cells/&micro;L</p></td></tr><tr><td><p>&le;&nbsp;200</p></td><td><p>34/41 (83&nbsp;%)</p></td><td><p>43/61 (70&nbsp;%)</p></td><td><p>27/42 (64&nbsp;%)</p></td><td><p>35/43 (81&nbsp;%)</p></td></tr><tr><td><p>&gt;&nbsp;200</p></td><td><p>285/323 (88&nbsp;%)</p></td><td><p>260/294 (88&nbsp;%)</p></td><td><p>278/304 (91&nbsp;%)</p></td><td><p>255/288 (89&nbsp;%)</p></td></tr><tr><td colspan="5"><p>NRTI background therapy&nbsp;&nbsp;</p></td></tr><tr><td><p>TDF/FTC</p></td><td><p>276/316 (87&nbsp;%)</p></td><td><p>267/312 (86&nbsp;%)</p></td><td colspan="2" rowspan="2"><p>NA</p></td></tr><tr><td><p>ABC/3TC</p></td><td><p>43/48 (90&nbsp;%)</p></td><td><p>36/43 (84&nbsp;%)</p></td></tr><tr><td colspan="5"><p>Viral subtype&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p>B</p></td><td><p>222/254 (87&nbsp;%)</p></td><td><p>219/255 (86&nbsp;%)</p></td><td><p>194/222 (87&nbsp;%)</p></td><td><p>199/226 (88&nbsp;%)</p></td></tr><tr><td><p>non-B</p></td><td><p>97/110 (88&nbsp;%)</p></td><td><p>84/100 (84&nbsp;%)</p></td><td><p>109/122 (89&nbsp;%)</p></td><td><p>91/105 (87&nbsp;%)</p></td></tr><tr><td colspan="5"><p><strong>Mean CD4 change from baseline</strong></p></td></tr><tr><td><p>Week&nbsp;48</p></td><td><p>193</p></td><td><p>186</p></td><td><p>198</p></td><td><p>188</p></td></tr><tr><td><p>Week&nbsp;96</p></td><td><p>224</p></td><td><p>207</p></td><td><p>238</p></td><td><p>223</p></td></tr></tbody></table><p>*For Week&nbsp;96, certain subjects with missing HIV‑1 RNA were excluded from the analysis.</p><p>&nbsp;</p><p>P007 was a Phase 2b trial in antiretroviral treatment-na&iuml;ve HIV‑1 infected adult subjects (n = 340). In Part I, subjects were randomised to receive one of 4 doses of doravirine or EFV, each in combination with FTC/TDF. After week&nbsp;24, all subjects randomised to receive doravirine were switched to (or maintained on) doravirine 100&nbsp;mg. Additional subjects were randomised in Part II to receive either doravirine 100&nbsp;mg or EFV, each in combination with FTC/TDF. In both parts of the trial, doravirine and EFV were administered as blinded-therapy and FTC/TDF was administered open-label.</p><p>&nbsp;</p><p><strong>Table 5: Efficacy response at week&nbsp;24 (Snapshot approach)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Doravirine 25&nbsp;mg</p><p>&nbsp;</p><p>(N=40)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Doravirine</p><p>50&nbsp;mg</p><p>&nbsp;</p><p>(N=43)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Doravirine 100&nbsp;mg</p><p>&nbsp;</p><p>(N=42)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Doravirine 200&nbsp;mg</p><p>&nbsp;</p><p>(N=41)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Efavirenz</p><p>600&nbsp;mg</p><p>&nbsp;</p><p>(N=42)</p><p>n (%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>HIV</strong>‑<strong>1 RNA &lt;&nbsp;40 copies/mL</strong></p></td><td style="vertical-align:top"><p>32 (80)</p></td><td style="vertical-align:top"><p>32 (74)</p></td><td style="vertical-align:top"><p>30 (71)</p></td><td style="vertical-align:top"><p>33 (80)</p></td><td style="vertical-align:top"><p>27 (64)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment differences</strong><strong><sup> &dagger;</sup></strong><strong> </strong></p><p><strong>(95&nbsp;% CI)</strong><strong><sup> &dagger;&dagger;</sup></strong></p></td><td style="vertical-align:top"><p>16 (-4, 34)</p></td><td style="vertical-align:top"><p>10 (-10, 29)</p></td><td style="vertical-align:top"><p>6.6 (-13, 26)</p></td><td style="vertical-align:top"><p>16 (-3, 34)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean CD4 change from baseline (cells/mm<sup>3</sup>) <sup>** </sup></strong></p></td><td style="vertical-align:top"><p>154</p></td><td style="vertical-align:top"><p>113</p></td><td style="vertical-align:top"><p>134</p></td><td style="vertical-align:top"><p>141</p></td><td style="vertical-align:top"><p>121</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>&dagger;</sup>A positive value favours doravirine over efavirenz.</p><p><sup>&dagger;&dagger;</sup>The 95&nbsp;% CIs were calculated using Miettinen and Nurminen&rsquo;s method with weights proportional to the size of each stratum (screening HBV-1 RNA &gt;&nbsp;100,000 copies/mL or &le;&nbsp;100,000 copies/mL.</p><p><sup>**</sup>Approach to handle missing data: Observed Failure (OF) approach. Baseline CD4 cell count was carried forward for subjects who discontinued assigned therapy due to lack of efficacy.</p><p>Note: Both doravirine and efavirenz were administered with emtricitabine/tenofovir disoproxil (FTC/TDF).</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Virologically suppressed adult subjects</em></p><p>The efficacy of switching from a baseline regimen consisting of two nucleoside reverse transcriptase inhibitors in combination with a ritonavir- or cobicistat-boosted PI, or cobicistat-boosted elvitegravir, or an NNRTI to DOR/3TC/TDF was evaluated in a randomised, open-label trial (DRIVE-SHIFT), in virologically suppressed HIV-1 infected adults.&nbsp; Subjects must have been virologically suppressed (HIV-1 RNA &lt;&nbsp;40 copies/mL) on their baseline regimen for at least 6&nbsp;months prior to trial entry, with no history of virologic failure, and a documented absence of RT substitutions conferring resistance to doravirine, lamivudine and tenofovir (see section, Resistance).&nbsp; Subjects were randomised to either switch to DOR/3TC/TDF at baseline [N = 447, Immediate Switch Group (ISG)], or stay on their baseline regimen until Week&nbsp;24, at which point they switched to DOR/3TC/TDF [N = 223, Delayed Switch Group (DSG)].&nbsp; At baseline, the median age of subjects was 43&nbsp;years, 16&nbsp;% were female, and&nbsp;24&nbsp;% were non-white.</p><p>&nbsp;</p><p>In the DRIVE-SHIFT trial, an immediate switch to DOR/3TC/TDF was demonstrated to be non-inferior at Week&nbsp;48 compared to continuation of the baseline regimen at Week&nbsp;24 as assessed by the proportion of subjects with HIV-1 RNA &lt;&nbsp;40 copies/mL. Treatment results are shown in Table&nbsp;6. Consistent results were seen for the comparison at study Week&nbsp;24 in each treatment group.</p><p><u>&nbsp;</u></p><p>Table 6: Efficacy response (Snapshot approach) in the DRIVE-SHIFT study</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Outcome</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>DOR/3TC/TDF</strong></p><p><strong>Once Daily ISG </strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Baseline Regimen DSG</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;48 </strong></p><p><strong>N=447</strong></p></td><td style="vertical-align:top"><p><strong>Week&nbsp;24 </strong></p><p><strong>N=223</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HIV-1 RNA &lt;&nbsp;40 copies/mL</strong></p></td><td style="vertical-align:top"><p>90&nbsp;%</p></td><td style="vertical-align:top"><p>93&nbsp;%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; ISG-DSG, Difference (95&nbsp;% CI)*</p></td><td colspan="2" style="vertical-align:top"><p>-3.6&nbsp;% (-8.0&nbsp;%, 0.9&nbsp;%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Proportion (%) of Subjects With HIV-1 RNA &lt;&nbsp;40 copies/mL by Baseline Regimen Received</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir- or Cobicistat-boosted PI</p></td><td style="vertical-align:top"><p>280/316 (89&nbsp;%)</p></td><td style="vertical-align:top"><p>145/156 (93&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>Cobicistat-boosted elvitegravir&nbsp;</p></td><td style="vertical-align:top"><p>23/25 (92&nbsp;%)</p></td><td style="vertical-align:top"><p>11/12 (92&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>NNRTI&nbsp;</p></td><td style="vertical-align:top"><p>98/106 (92&nbsp;%)</p></td><td style="vertical-align:top"><p>52/55 (95&nbsp;%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Proportion (%) of Subjects With HIV-1 RNA &lt;&nbsp;40 copies/mL by Baseline CD4<sup>+</sup> T cell Count (cells/mm<sup>3</sup>) </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; &lt;&nbsp;200 cells/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>10/13 (77&nbsp;%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3/4 (75&nbsp;%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;200 cells/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>384/426 (90&nbsp;%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>202/216 (94&nbsp;%)&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>HIV-1 RNA &ge;&nbsp;40 copies/mL</strong><strong><sup>&dagger;</sup></strong></p></td><td style="vertical-align:top"><p>3&nbsp;%</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>No Virologic Data Within the Time Window&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p>8&nbsp;%</p></td><td style="vertical-align:top"><p>3&nbsp;%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Discontinued study due to AE or Death<sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>3&nbsp;%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Discontinued study for Other Reasons<sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>4&nbsp;%</p></td><td style="vertical-align:top"><p>&nbsp; 3&nbsp;%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; On study but missing data in window&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*The 95&nbsp;% CI for the treatment difference was calculated using stratum-adjusted Mantel-Haenszel method.</p><p><sup>&dagger;</sup>Includes subjects who discontinued study drug or study before Week&nbsp;48 for ISG or before Week&nbsp;24 for DSG for lack or loss of efficacy and subjects with HIV-1 RNA &ge;&nbsp;40 copies/mL in the Week&nbsp;48 window for ISG and in the Week&nbsp;24 window for DSG.</p><p><sup>&Dagger;</sup>Includes subjects who discontinued because of adverse event (AE) or death if this resulted in no virologic data on treatment during the specified window.</p><p><sup>&sect;</sup>Other reasons include: lost to follow-up, non-compliance with study drug, physician decision, protocol deviation, withdrawal by subject.</p><p>Baseline Regimen = ritonavir or cobicistat-boosted PI (specifically atazanavir, darunavir, or lopinavir), or</p><p>cobicistat-boosted elvitegravir, or NNRTI (specifically efavirenz, nevirapine, or rilpivirine), each</p><p>administered with two NRTIs.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Discontinuation due to adverse events</u></p><p>In a pooled analysis combining data from two treatment-na&iuml;ve trials (P007 and DRIVE‑AHEAD), a lower proportion of subjects who discontinued due to an adverse event by week&nbsp;48 was seen for the combined doravirine (100&nbsp;mg) treatment groups (2.8&nbsp;%) compared with the combined EFV treatment group (6.1&nbsp;%) (treatment difference -3.4&nbsp;%, p-value 0.012).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>The efficacy of doravirine was evaluated in combination with lamivudine and tenofovir disoproxil (DOR/3TC/TDF) in an open-label, single-arm trial in HIV-1 infected paediatric patients 12 to less than 18&nbsp;years of age (IMPAACT 2014 (Protocol 027)).</p><p>&nbsp;</p><p>At baseline, the median age of subjects was 15 years (range: 12 to 17), 58% were female, 78% were Asian and 22% were Black, and the median CD4+ T-cell count was 713&nbsp;cells per mm<sup>3</sup> (range: 84 to 1,397). After switching to DOR/3TC/TDF, 95% (41/43) of virologically suppressed subjects remained suppressed (HIV-1 RNA &lt; 50&nbsp;copies/mL) at Week&nbsp;24 and 93% (40/43) remained suppressed (HIV-1 RNA &lt; 50 copies/mL) at Week 48.</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with<br />doravirine in one or more subsets of the paediatric population in treatment of human immunodeficiency virus-1 (HIV‑1) infection, as per Paediatric Investigation Plan (PIP) decision in the granted indication. See section&nbsp;4.2 for information on paediatric use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The pharmacokinetics of doravirine were studied in healthy subjects and HIV‑1 infected subjects. Doravirine pharmacokinetics are similar in healthy subjects and HIV‑1-infected subjects. Steady state was generally achieved by Day&nbsp;2 of once daily dosing, with accumulation ratios of 1.2 to 1.4 for AUC<sub>0-24</sub>, C<sub>max</sub>, and C<sub>24</sub>. Doravirine steady state pharmacokinetics following administration of 100&nbsp;mg once daily to HIV‑1 infected subjects, based on a population pharmacokinetics analysis, are provided below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Parameter</p><p>GM (%&nbsp;CV)</p></td><td><p>AUC<sub>0-24 </sub></p><p>&micro;g&bull;h/mL</p></td><td><p>C<sub>max</sub></p><p>&micro;g/mL</p></td><td><p>C<sub>24</sub></p><p>&micro;g/mL</p></td></tr><tr><td><p>Doravirine</p><p>100&nbsp;mg</p><p>once daily</p></td><td><p>16.1 (29)</p></td><td><p>0.962 (19)</p></td><td><p>0.396 (63)</p></td></tr><tr><td colspan="4"><p>GM: Geometric mean, %&nbsp;CV: Geometric coefficient of variation</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Following oral dosing, peak plasma concentrations are achieved 2&nbsp;hours after dosing. Doravirine has an estimated absolute bioavailability of approximately 64&nbsp;% for the 100&nbsp;mg tablet.</p><p>&nbsp;</p><p><u>Effect of food on oral absorption</u></p><p>The administration of a single doravirine tablet with a high-fat meal to healthy subjects resulted in a 16&nbsp;% and 36&nbsp;% increase in doravirine AUC and C<sub>24, </sub>respectively, while C<sub>max</sub> was not significantly affected.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>Based on administration of an IV microdose, the volume of distribution of doravirine is 60.5&nbsp;L. Doravirine is approximately 76&nbsp;% bound to plasma proteins.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>Based on <em>in vitro</em> data, doravirine is primarily metabolised by CYP3A.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>Doravirine has a terminal half-life (t<sub>1/2</sub>) of approximately 15&nbsp;hours. Doravirine is primarily eliminated via oxidative metabolism mediated by CYP3A4. Biliary excretion of unchanged medicinal product may contribute to the elimination of doravirine, but this elimination route is not expected to be significant. Excretion of unchanged medicinal product via urinary excretion is minor.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Renal excretion of doravirine is minor. In a study comparing 8 subjects with severe renal impairment to 8 subjects without renal impairment, the single dose exposure of doravirine was 31&nbsp;% higher in subjects with severe renal impairment. In a population pharmacokinetic analysis, which included subjects with CrCl between 17 and 317&nbsp;mL/min, renal function did not have a clinically relevant effect on doravirine pharmacokinetics. No dose adjustment is required in patients with mild, moderate or severe renal impairment. Doravirine has not been studied in patients with end-stage renal disease or in patients undergoing dialysis (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Doravirine is primarily metabolised and eliminated by the liver. There was no clinically relevant difference in the pharmacokinetics of doravirine in a study comparing 8 subjects with moderate hepatic impairment (classified as Child-Pugh score B primarily due to increased encephalopathy and ascites scores) to 8 subjects without hepatic impairment. No dose adjustment is required in patients with mild or moderate hepatic impairment. Doravirine has not been studied in subjects with severe hepatic impairment (Child-Pugh score C) (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Paediatric population&nbsp; </u></p><p>Mean doravirine exposures were similar in 54 paediatric patients aged 12 to less than 18&nbsp;years and weighing at least 35&nbsp;kg who received doravirine or doravirine/lamivudine/tenofovir disoproxil in IMPAACT 2014 (Protocol&nbsp;027) relative to adults following administration of doravirine or doravirine/lamivudine/tenofovir disoproxil (Table 7).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 7: Steady state pharmacokinetics for doravirine following administration of doravirine or doravirine/lamivudine/tenofovir disoproxil in HIV infected paediatric patients aged 12 to less than 18&nbsp;years and weighing at least 35&nbsp;kg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Parameter*</strong></p></td><td style="vertical-align:top"><p><strong>Doravirine</strong><sup>&dagger;</sup></p></td></tr><tr><td><p>AUC<sub>0-24</sub></p><p>(&micro;g&bull;h/mL)</p></td><td><p>16.4 (24)</p></td></tr><tr><td><p>C<sub>max</sub></p><p>(&micro;g/mL)</p></td><td style="vertical-align:top"><p>1.03 (16)</p></td></tr><tr><td><p>C<sub>24</sub></p><p>(&micro;g/mL)</p></td><td style="vertical-align:top"><p>0.379 (42)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*Presented as geometric mean (%CV: geometric coefficient of variation)</p><p><sup>&dagger;</sup>From population PK analysis (n=54)</p><p>Abbreviations: AUC=area under the time concentration curve; C<sub>max</sub>=maximum concentration; C<sub>24</sub>=concentration at 24&nbsp;hours</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Elderly</u></p><p>Although a limited number of subjects aged 65&nbsp;years and over has been included (n=36), no clinically relevant differences in the pharmacokinetics of doravirine have been identified in subjects at least 65&nbsp;years of age compared to subjects less than 65&nbsp;years of age in a Phase 1 trial or in a population pharmacokinetic analysis. No dose adjustment is required.</p><p>&nbsp;</p><p><u>Gender</u></p><p>No clinically relevant pharmacokinetic differences have been identified between men and women for doravirine.</p><p>&nbsp;</p><p><u>Race</u></p><p>No clinically relevant racial differences in the pharmacokinetics of doravirine have been identified based on a population pharmacokinetic analysis of doravirine in healthy and HIV‑1 infected subjects.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Reproductive toxicity</u></p><p>Reproduction studies with orally administered doravirine have been performed in rats and rabbits at exposures approximately 9 times (rats) and 8 times (rabbits) the exposure in humans at the recommended human dose (RHD) with no effects on embryo-foetal (rats and rabbits) or pre/postnatal (rats) development. Studies in pregnant rats and rabbits showed that doravirine is transferred to the foetus through the placenta, with foetal plasma concentrations of up to 40&nbsp;% (rabbits) and 52&nbsp;% (rats) that of maternal concentrations observed on gestation Day&nbsp;20.</p><p>&nbsp;</p><p>Doravirine was excreted into the milk of lactating rats following oral administration, with milk concentrations approximately 1.5 times that of maternal plasma concentrations.</p><p>&nbsp;</p><p><u>Carcinogenesis</u></p><p>Long-term oral carcinogenicity studies of doravirine in mice and rats showed no evidence of carcinogenic potential at estimated exposures up to 6 times (mice) and 7 times (rats) the human exposures at the RHD.</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>Doravirine was not genotoxic in a battery of <em>in vitro</em> or <em>in vivo</em> assays.</p><p><u>&nbsp;</u></p><p><u>Impairment of fertility</u></p><p>There were no effects on fertility, mating performance or early embryonic development when doravirine was administered to rats up to 7 times the exposure in humans at the RHD.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core </u></p><p>Croscarmellose sodium (E468)</p><p>Hypromellose acetate succinate</p><p>Lactose monohydrate</p><p>Magnesium stearate (E470b)</p><p>Microcrystalline cellulose (E460)</p><p>Silica, colloidal anhydrous (E551)</p><p>&nbsp;</p><p><u>Film-coating</u></p><p>Carnauba wax (E903)</p><p>Hypromellose (E464)</p><p>Lactose monohydrate</p><p>Titanium dioxide (E171)</p><p>Triacetin (E1518)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months
After first opening of the bottle use within 35 days.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 300C.&nbsp;</p><p>Store in the original bottle and keep the bottle tightly closed in order to protect from moisture.<strong> </strong>Do not remove the desiccant. This medicinal product does not require any special temperature storage conditions. For storage conditions after first opening of the bottle see section&nbsp;6.3.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each carton contains a high density polyethylene (HDPE) bottle with a polypropylene child-resistant closure with silica gel desiccant.</p><p>&nbsp;</p><p>The following pack sizes are available:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 bottle with 30 film-coated tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 90 film-coated tablets (3 bottles of 30 film-coated tablets).</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem 
The Netherlands

Manufacturer:
MSD International GmbH, Kilsheelan, Clonmel, Co. Tipperary, Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>